SCHEMBL9933174

SCHEMBL9933174

c1ccc([C@@H](C2CC2)N2CCNCC2)nc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNA5 P22460 3/20 0.45
PLD1 Q13393 1/20 0.45
KCNE1 P15382 1/20 0.45
SLC6A4 P31645 5/20 0.45
SLC6A2 P23975 4/20 0.43
SLC6A3 Q01959 3/20 0.41
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
HTR7 P34969 2/20 0.39
ALDH1A1 P00352 2/20 0.38
CYP2D6 P10635 2/20 0.38
KDM4E B2RXH2 1/20 0.38
LMNA P02545 1/20 0.38
CYP3A4 P08684 1/20 0.38
MAPT P10636 1/20 0.38
CYP2C19 P33261 1/20 0.38
KCNH2 Q12809 1/20 0.38
CACNA2D1 P54289 1/20 0.37
CACNA1B Q00975 1/20 0.37
CACNB1 Q02641 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9933176 1.00 KCNA5 (0.45) KCNA5PLD1KCNE1SLC6A4SLC6A2
SCHEMBL9934759 1.00 KCNA5 (0.45) KCNA5PLD1KCNE1SLC6A4SLC6A2
SCHEMBL9963447 0.82 IDH1 (0.47) KCNA5KCNE1MEN1KMT2AALDH1A1
SCHEMBL16182262 0.82 IDH1 (0.48) KCNA5KCNE1SLC6A3ALDH1A1CYP2D6
SCHEMBL3653738 0.80 KCNA5 (0.41) KCNA5PLD1KCNE1SLC6A4SLC6A2
SCHEMBL3653736 0.80 KCNA5 (0.41) KCNA5PLD1KCNE1SLC6A4SLC6A2
SCHEMBL3653741 0.80 KCNA5 (0.41) KCNA5PLD1KCNE1SLC6A4SLC6A2
SCHEMBL8304948 0.79 MEN1 (0.55) KCNA5PLD1KCNE1SLC6A4MEN1
SCHEMBL9377121 0.78 SLC6A4 (0.40) KCNA5PLD1KCNE1SLC6A4SLC6A2
SCHEMBL9933454 0.76 KCNA5 (0.49) KCNA5PLD1KCNE1SLC6A4MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2470021-B1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME (US) 2014-10-22 EP disclosed
US-8354403-B2 Pyrrolidine derived beta 3 adrenergic receptor agonists MERCK SHARP & DOHME CORP. (US) 2013-01-15 US disclosed
US-8354403-B2 Pyrrolidine derived beta 3 adrenergic receptor agonists MERCK SHARP & DOHME CORP. (US) 2013-01-15 US disclosed
US-8354403-B2 Pyrrolidine derived beta 3 adrenergic receptor agonists MERCK SHARP & DOHME CORP. (US) 2013-01-15 US disclosed
US-20120157432-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME, CORP. (US) 2012-06-21 US disclosed
US-20120157432-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME, CORP. (US) 2012-06-21 US disclosed
US-20120157432-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME, CORP. (US) 2012-06-21 US disclosed
WO-2011025690-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME CORP. (US) 2011-03-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157432-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS ADRB3, ADRB1, ADRB2 KCNA5 865/4885PLD1 2087/4885KCNE1 1207/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.